NEDRA HARRINGTON: Open Payments
NPI 1386805786 · POTOSI, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$900 in 37 payments from 13 companies in 2025. Trend: 2023 $2,481 · 2024 $1,393 · 2025 $900
Food & beverage: $900
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $260 |
| Alexion Pharmaceuticals, Inc. | 2 | $97 |
| Janssen Biotech, Inc. | 4 | $85 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $85 |
| Novo Nordisk Inc | 2 | $80 |
| Teva Pharmaceuticals USA, Inc. | 1 | $73 |
| Sandoz Inc. | 2 | $53 |
| UCB, Inc. | 2 | $37 |
| Amgen Inc. | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
Products named: VRAYLAR, TREMFYA, XIFAXAN, Ozempic, AUSTEDO XR, RINVOQ, QULIPTA, HYRIMOZ.
Industry payments across MO — which companies pay providers there.
